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Summary The aim of this study was to investigate the link between protein kinase C (PKC) and multidrug resistance (mdr) phenotype. The
expression of both was studied in doxorubicin-resistant MCF-7/Adr cells as they reverted to the wild-type phenotype when cultured in the
absence of drug. The following parameters were measured in cells 4, 10, 15, 20 and 24 weeks after removal of doxorubicin; (1) sensitivity of
the cells towards doxorubicin; (2) levels of P-glycoprotein (P-gp) and MDR1 mRNA; (3) levels and cellular localization of PKC isoenzyme
proteins cx, 0 and e; and (4) gene copy number of PKC-a and MDR1 genes. Cells lost their resistance gradually with time, so that by week 24
they had almost completely regained the drug sensitivity seen in wild-type MCF-7 cells. P-gp levels measured by Western blot mirrored the
change in doxorubicin sensitivity. By week 20, P-gp had decreased to 18% of P-gp protein levels at the outset, and P-gp was not detectable
at week 24. Similarly, MDR1 mRNA levels had disappeared by week 24. MCF-7/Adr cells expressed more PKCs-a and -0 than wild-type cells
and possessed a different cellular localization of PKC-c. The expression and distribution pattern of these PKCs did not change for up to 20
weeks, but reverted back to that seen in wild-type cells by week 24. MDR1 gene amplification remained unchanged until week 20, but then
was lost precipitously between weeks 20 and 24. The PKC-a gene was not amplified in MCF-7/Adr cells. The results suggest that MCF-7/Adr
cells lose MDR1 gene expression and PKC activity in a co-ordinate fashion, consistent with the existence of a mechanistic link between
MDR1 and certain PKC isoenzymes.
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The chemotherapy of many tumours is complicated either at the
outset or during treatment by intrinsic or acquired multidrug resis-
tance (mdr) against cytotoxic drugs. Prominent among the mecha-
nisms by which cells protect themselves against cytotoxicity is
overexpression of the plasma membrane drug efflux pump, P-
glycoprotein (P-gp). P-gp uses ATP actively to extrude drugs, and
so reduce their intracellular concentration to less than therapeutic
levels (Gottesman and Pastan, 1993). One of the mechanisms by
which P-gp activity is regulated is via protein phosphorylation
(Chambers et al, 1993, 1994; German et al, 1996; Goodfellow et
al, 1996), and several lines of evidence suggest that the protein
kinase C (PKC) family is involved in P-gp phosphorylation. PKC
activity and levels are increased in many mdr cell lines, including
human breast-derived MCF-7/Adr cells (Fine et al, 1988). Murine
sarcoma S180 cells exposed to doxorubicin for I h displayed
markedly increased PKC activity, suggesting a link with early
events involved in the selection of drug-resistant cells (Posada et
al, 1989). Furthermore, levels of PKC activity are directly corre-
lated with the degree of P-gp-mediated mdr in murine fibrosar-
coma cells (O'Brian et al, 1989). Among the different PKC
isoenzymes, PKC-x has been particularly associated with the mdr
phenotype. PKC-at levels are raised in many mdrcells, and expres-
sion of PKC-a antisense cDNA decreased the mdr phenotype in
drug-resistant MCF-7 cells (Ahmad and Glazer, 1993). Inhibition
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of PKC-aL by N-myristoylated peptide containing a sequence
corresponding to the pseudosubstrate region of PKC-ox partially
reversed mdr in MCF-7/Adr cells via enzyme inhibition (Gupta et
al, 1996). Furthermore, transfection ofMCF-7 cells with the PKC-
x and MDRJ genes conferred greater resistance onto cells than
transfection with MDRJ alone (Yu et al, 1991). Treatment of
multidrug-resistant cells with PKC activators, such as the tumour-
promoting phorbol ester tetradecanoylphorbol-13-acetate,
increased P-gp phosphorylation in K562/Adr erythroleukaemia
(Hamada et al, 1987), MCF-7/Adr (Fine et al, 1988) and KB-V1
cells (Chambers et al, 1990). PKC activators also increased drug
accumulation and decreased drug sensitivity in MCF-7/Adr (Fine
et al, 1988) and KM12L4a cells (Dong et al, 1991), and induced
MDRJ gene expression in normal human lymphocytes (Chaudhary
and Roninson, 1992). Conversely, a variety of PKC inhibitors,
such as staurosporine (Sato et al, 1990), the staurosporine
analogues CGP 41251 (Utz et al, 1994; Budworth et al, 1996) and
GF 109203X (Gekeler et al, 1996), calphostin C (Bates et al, 1993)
and safingol (Sachs et al, 1995), reversed P-gp-mediated mdr.
However, reversal of drug resistance caused by staurosporine
analogues is probably associated with direct interaction with P-gp
rather than with PKC inhibition (Smith and Zilfou, 1995; Gekeler
et al, 1996; Goodfellow et al, 1996; Budworth et al, 1996). The
aim ofthis study was to investigate the link between PKC and mdr
by analysis ofchanges in expression ofthe PKC and MDR] genes
in drug-selected mdr cells, cultured without the selective pressure
ofdrug in the medium. Specifically, we compared the time course
of change in the following parameters using MCF-7/Adr cells
grown in the absence of doxorubicin: (1) sensitivity against
doxorubicin; (2) levels of P-gp and MDRI mRNA; and (3) levels
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Figure 1 Time course of sensitivity against doxorubicin of MCF-7/Adr cells
cultured in the absence of doxorubicin. IC50 values were determined as
described under Materials and methods. Values are the means of two
determinations
O-
and localization of the major PKC isoenzymes found in these
cells, x, £ and 0. The results show a remarkable synchrony
between reacquisition of drug sensitivity, loss of P-gp and MDRI
mRNA, and reversion to the PKC isoenzyme pattern of wild-type
MCF-7 cells.
MATERIALS AND METHODS
Cell growth
MCF-7 and MCF-7/Adr cells were provided by J Carmichael
(University ofNottingham, UK); the latter were originally derived
by K Cowan (NCI, Bethedsda, USA). Cells were grown in RPMI-
1640 medium with glutamine, penicillin/streptomycin and 10%
heat-inactivated fetal calf serum (Gibco, Paisley, UK). Cells were
subcultured when they were confluent. Routinely, MCF-7/Adr
cells were maintained in 0.5 gM doxorubicin. For IC50 determina-
tions, cells were grown in six-well dishes (Nunclon) and counted
after 4 days in culture (four doubling times).
Western blot analysis
Cells were fractionated into cytosolic, particulate (which contains
membranes and structural proteins) and nuclear fractions. Western
blot analysis of PKC isoenzymes was performed as described
previously (Stanwell et al, 1994) using monoclonal antibodies
against PKCs-a (TCS, Boltoph Claydon, UK), -£, -0 (Affiniti,
Nottingham, UK) and P-gp (C219; ID Labs., Glasgow, UK) and a
polyclonal antibody against PKC-1 (Gibco BRL). Equal amounts
ofprotein were loaded to allow quantitation by laser densitometry.
Northern blot, reverse transcription-polymerase chain
reaction and Southern blot analyses
RNA was isolated from cells using Trizol (Gibco BRL). Aliquots
ofthe RNA solution (10 ig) were used forNorthem blotting. Blots
were hybridized with a 32P-labelled pHDR5A probe, as previously
described (Ueda et al, 1987). Blots were washed, visualized by
autoradiography and quantitated by laser densitometry (Molecular
Dynamics, Sunnydale, USA).
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Figure 2(A) P-glycoprotein expression in MCF-7/Adr cells cultured in the
absence of doxorubicin, as determined by Western blot using C219 antibody
(top) and quantitated by laser densitometry (bottom), comparing it with the
value in week 0 (100%). (B)MDR1 mRNA levels in wild-type MCF-7 cells
(WT), MCF-7/Adr cells and MCF-7/Adr cells cultured in the absence of
doxorubicin, as determined by Northern blot (top) and quantitated by laser
densitometry (bottom). Values in the graphs are expressed as a percentage
of the density readings in cells from which doxorubicin had just been
removed (week 0). Numbers above blots indicate week of culture. In
(B)MDR1 and GAPDH mRNAs are localized at 4.40 and 1.27 kb
respectively; quantitation is normalized by GAPDH expression. Experimental
details of the blotting are described under materials and methods. Blots are
representative of two determinations
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Figure 3 Expression of PKCs-a, -0 and -£ in MCF-7 (WT, wild-type) and
MCF-7/Adr cells at different times after removal of doxorubicin. Numbers
indicate week of culture. Details of antibodies and Western analysis are
described under materials and methods. Blots are representative of two
determinations
Semi-quantitative reverse transcription-polymerase chain reac-
tion (RT-PCR) was performed as described by Zhang et al (1996),
using a titration analysis and 3P-labelled primers specific for
PKC-oc and -0. The following forward and reverse primers for
PKC-oc were used: GAGAAGAGGGGGCGGATTTAC and
AAGGTTGTTGGAAGGTT GTTT, corresponding to bases
470-490 and 973-993 respectively (taking the adenosine of the
translational start site as base 1), which resulted in a PCR product
of 523 bp. Similarly for PKC-0, primers TTTCTTCGGATTG-
GCTTGTC and TGGTCTTTCTTTGTTCAGTT were used, corre-
sponding to bases 10-29 and 1089-1108 respectively, which
resulted in a PCR product of 1098 bp. Twenty-eight cycles ofPCR
were performed using 10 ng of RNA. Annealing temperature was
50°C, and primer concentration was 0.5 pmol gl-' in the PCR step.
RT was performed before PCR as described before (Zhang et al,
1996). The PCR products were separated by electrophoresis on
an 8% polyacrylamide gel. The gel was dried and bands were
visualized and quantitated using a phosphorimager (Molecular
Dynamics). To assess gene amplification, genomic DNA was
isolated from 2 x 107 cells using a Qiagen kit (Dorking, UK). DNA
was digested with EcoRl (Gibco BRL) at 37°C overnight and
separated by electrophoresis on 0.8% agarose. After blotting onto
Hybond N+ (Amersham International, UK), DNA was hybridized
with a random primer-labelled pHDR5A probe, as previously
described (Ueda et al, 1987). After detection, the blot was stripped
and reprobed with a 32P-labelled PKC-oc probe. Blots were visual-
ized and quantitated by laser densitometry.
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Figure 4 Levels of PKCs-oc (0) and-H (El) mRNA in MCF-7 (WT) and MCF-
7/Adr cells at different times after removal of doxorubicin. Semi-quantitative
RT-PCR was performed using 10 ng of cellular RNA, and PCR products
were quantitated by phosphorimaging, as described under materials and
methods. Values are the means of two determinations
RESULTS
Sensitivity towards doxorubicin
Cells were cultured in the absence of doxorubicin and resistance
was monitored at 4- to 5-week intervals. Cellular sensitivity
increased with time (Figure 1). The ICs, for doxorubicin was
initially 2020 ± 400 nm, and decreased gradually to 1600, 860 and
180 nm after 10, 15 and 20 weeks respectively. After 24 weeks, the
IC 50 had reverted back to a value (10 nM) that was only slightly
above that observed for wild-type MCF-7 cells (5 nM).
P-gp and MDR1 levels
P-gp protein and MDR1 mRNA levels were monitored by Western
and Northern blot analyses respectively (Figure 2). P-gp was
immunodetected in MCF-7/Adr but not in wild-type MCF-7 cells
(Davies et al, 1996). P-gp expression decreased gradually to 82%
of the initial level by week 15, 18% by week 20 and undetectable
levels at week 24 after drug removal (Figure 2A). MDR] mRNA
levels in MCF-7/Adr cells declined gradually to 63% ofthe initial
value by week 10, 56% by week 15, 40% by week 20 and 1% by
week 24 after drug removal. After this time, levels were compa-
rable with those seen in wild-type cells.
PKC isoenzyme protein levels
PKC isoenzymes in MCF-7/Adr cells were compared with those in
MCF-7 cells. As described by us previously (Davies et al, 1996),
PKC- x was overexpressed in the cytosol, and PKC-0 in all three
fractions ofMCF-7/Adr compared with wild-type cells. The distri-
bution of PKC-e in MCF-7/Adr was different from that in MCF-7
cells, in that in wild-type cells PKC-e was localized in the cytosol,
whereas in MCF-7/Adr cells, less was in the cytosol and more in
the membrane and nuclear fractions. There was no significant
difference between the two lines in level and localization of
PKC-1. PKCs-f, -y and -6 were not detectable at the protein level
in wild type or MCF-7/Adr cells (results not shown). Levels of
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Figure 5 MDR1 (A) and PKC-oa (B) gene levels in MCF-7 (WT) and MCF-
7/Adr cells cultured in the absence of doxorubicin. Digits at the top indicate
week of culture; on the side, number of base pairs. Gels of genomic DNA
were analysed by Southern blot and hybridized with a probe for MDR1 (A),
subsequently with one for PKC-a (B), and bands were visualized by
autoradiography as described under materials and methods. As the MDR1
probe does not discriminate between MDR1 and MDR2, bands shown in (A)
correspond to fragments from both genes. In separate experiments, gels
were hybridized with a specific MDR2probe (not shown), and by comparison
the MDR1 gene fragment was characterized (arrow)
PKC-cx, -£ and -0 were monitored in cells that regained drug sensi-
tivity on culture without doxorubicin. PKC-x and -0 were
detectable at similar levels up to week 20, but expression was lost
by week 24 (Figure 3). PKC-e was found in the membrane and
nucleus until week 20, but by week 24 it was only detectable in the
cytosol, mimicking the pattern observed in wild-type MCF-7 cells.
PKC isoenzyme mRNA levels
In order to assess changes at the message level for PKCs-ax and -0,
cellular RNA was analysed by semi-quantitative RT-PCR. PKC-a
mRNA was detected in wild-type cells and greatly enhanced in
MCF-7/Adr cells. PKC-0 mRNA in wild-type cells was at the
detection limit, but in MCF-7/Adr cells it was clearly detectable
(results not shown). As MCF-7/Adr cells regained drug sensitivity,
PKC-0 mRNA levels remained elevated up to week 20, but by
week 24 had decreased to values measured in wild-type cells
(Figure 4).
MDR1 and PKC-a gene amplification
Cells selected for resistance against cytotoxic agents often contain
an amplified MDRI gene (Riordan et al, 1985; Fairchild et al,
1987). Therefore, the MDR] gene copy number was followed in
MCF-7/Adr cells as they regained drug sensistivity by Southern
blot analysis (Figure 5A). The use ofdifferential probes for MDR]
and MDR2 genes (data not shown) confirmed that the band near
1000 bp (marked by an arrow in Figure 5A) was caused by
hybridization with MDRJ. Amplification of the gene was seen up
to week 20, but lost entirely by week 24. There was no gene ampli-
fication in wild-type cells. We tested the hypothesis that increased
PKC-a mRNA levels in MCF-7/Adr cells was also the result of
gene amplification. Southern analysis shows that PKC-a gene
levels in the resistant cells were similar to those in the revertant
cells (Figure 5B). Thus, the PKC-a gene was not amplified in
MCF-7/Adr cells.
DISCUSSION
Our results describe, for the first time, the detailed time course of
changes in sensitivity against doxorubicin, P-gp expression and
PKC isoenzyme levels in MCF-7/Adr cells cultured in the absence
of drug. The following two conclusions help characterize the
nature of the link between mdr and PKC: (1) the decrease in mdr
phenotype and the restoration ofthe PKC expression pattern to that
observed in wild-type cells are remarkably synchronous; (2) apart
from PKC-a, PKC-0 may play arole in the maintenance ofthe mdr
phenotype. Protein levels ofboth these isoenzymes are elevated in
MCF-7/Adr compared with wild-type MCF-7 cells, whereas those
ofPKC-s are decreased (Blobe et al, 1993; Davies et al, 1996).
PKC phosphorylates P-gp at three serine sites within the linker
region of the P-gp molecule (Chambers et al, 1995). PKC-catal-
ysed P-gp phosphorylation has been thought to increase the
affinity ofthe pump for cytotoxic drugs (Bates et al, 1992) or drug
transport velocity (Aftab et al, 1994). However, recently, mutation
of the PKC-phosphorylation sites in the P-gp molecule has been
shown to be without consequence for its normal drug transport
function (Germann et al, 1996; Goodfellow et al, 1996).
Furthermore, down-regulation of PKC with bryostatin 1, which
decreased P-gp phosphorylation, did not affect P-gp function
(Scala et al, 1995). Taken together, these results demonstrate that
PKC-mediated phosphorylation of P-gp may well be functionally
redundant, and PKC may regulate the mdr phenotype via events
upstream ofP-gp, such as MDR] transcription.
Of the PKC isoenzymes, PKC-x has most commonly been
considered as aregulator ofmdrphenotype (see Introduction). Our
result that PKC-0 is also overexpressed in MCF-7/Adr cells and
thus may affect mdr is consistent with a recent clinical report of a
concordant increase in the expression of the PKC-0 and MDR]
genes in leukaemia cells from relapsed AML patients (Beck et al,
1996). PKC-0 is an unusual nPKC isoenzyme because of its
unique tissue distribution; it is predominantly found in skeletal
muscle, lymphoid organs and haematopoietic cells (Baier et al,
1994). Its specific function is as yet unknown.
The results described above suggest that in order to maintain a
high level of resistance, MCF-7/Adr cells have to be cultured in
the continuing presence of doxorubicin, which is consistent with
several reports on the recovery of drug sensitivity in mdr cells
grown without the drug against which resistance has been induced
(Dahllof et al, 1984; Meyers et al, 1985; Fojo et al, 1985). Mdr
cells are characterized by an increased rate of both MDRJ tran-
scription and gene amplification (Morrow et al, 1992; Madden et
al, 1993; Davies et al, 1996). On removal ofdoxorubicin from the
culture medium, MDR] mRNA levels in MCF-7/Adr cells started
to decrease almost immediately, whereas MDR] gene amplifica-
tion was only lost more than 16 weeks later. This finding suggests
that the presence ofthe drug maintains increased MDRJ transcrip-
tion rate. Once MDR] mRNA had decreased to 40% ofthe initial
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level 20 weeks after drug removal, P-gp levels declined and,
concomitantly, cells commenced to regain sensitivity towards
doxorubicin.
When cells recovered drug sensitivity, the pattern ofexpression
and distribution of PKCs-a, -£ and-O reverted back to that seen in
wild-type cells. Although there have been many reports of PKC-oc
overexpression in resistant cells, the possibility of PKC-ox gene
amplification has, to our knowledge, not previously been consid-
ered. The genes for MDR1 and PKC-ax are localized on chromo-
somes 7 and 17 respectively (Fojo et al, 1986; Finkenzeller et al,
1990). Co-amplification of two genes that lie on separate chromo-
somes seems highly unlikely. The results outlined above show that
the PKC-oc gene was not amplified in MCF-7/Adr cells, so the
increase in PKC-ox expression is due either to an increased tran-
scription rate or to mRNA stabilization. That the PKC isoenzymes
reverted back to the wild-type pattern of expression at the same
time at which cells lost MDRJ gene amplification suggests that the
PKC and MDR genes, while not co-amplified, are tightly co-regu-
lated. The MCF-7/Adr cells used in this study comprise two
subpopulations, which contain low and high levels of MDR] gene
amplification and of P-gp (Davies et al, 1996). Although these
subpopulations are characterized by different degrees of resis-
tance, their PKC isoenzyme complement is identical (Davies et al,
1996). Therefore, the observed changes in PKC from wild-type to
doxorubicin-resistant cells is probably an early event in the devel-
opment ofdrug resistance. Consequently, it is conceivable that the
alterations in PKC, which happen during exposure to doxorubicin,
are a prerequisite for MDRJ gene amplification to occur.
In summary, this study has characterized the time course of
changes in doxorubicin sensitivity, P-gp and MDR] levels and
PKC isoenzyme protein and mRNA levels in MCF-7/Adr cells
during their reversion to the wild-type phenotype. The similarity in
loss of expression between MDR] and PKCs-oc and -0 suggests a
mechanistic link between them. The nature of this link remains
unclear, and we cannot exclude the possibility that MDRI affects
PKC expression, rather than vice versa. Nevertheless, PKCs-x, -£
and -0 might be important modulators of the mdr phenotype in
MCF-7/Adr cells, possibly via regulation ofthe MDR] gene.
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